Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health, Department of Health and Human Services, for the operation of a Small Molecule Repository. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/nih-awards-major-contract-to-evotec-to-manage-and-operate-a-small-molecule-repository-5075
Building innovation on the back of profitable growth
Evotec AG today reported financial results and corporate updates for the second quarter and first half of 2012 ending 30 June 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/building-innovation-on-the-back-of-profitable-growth-5073
CureBeta, a collaboration between Evotec and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Evotec AG today announced that it has licensed to Janssen Pharmaceuticals, Inc. a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/curebeta-a-collaboration-between-evotec-and-harvard-university-enters-strategic-alliance-with-janssen-pharmaceuticals-5067
CureBeta, a collaboration between Evotec AG and Harvard University enters strategic alliance with Janssen Pharmaceuticals
Evotec AG today announced that it has entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc. with a particular focus on the regeneration of insulin- producing beta cells. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/curebeta-a-collaboration-between-evotec-ag-and-harvard-university-enters-strategic-alliance-with-janssen-pharmaceuticals-5600
Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received
Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 4.0 million to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/milestone-payment-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-received-5065
Evotec Becomes the First Contract Research Facility in Europe to Offer Agilent's RapidFire/MS Screening for Pharmaceutical Drug Discovery
Evotec AG is proud to announce the addition of Agilent Technologies‘ RapidFire Mass Spectrometry analysis capabilities to their High Throughput Screening facilities in Hamburg. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-becomes-the-first-contract-research-facility-in-europe-to-offer-agilents-rapidfirems-screening-for-pharmaceutical-drug-discovery-5063
Evotec reports continued strong revenue growth in Q1 2012
Evotec AG today reported financial results and corporate updates for the first quarter of 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-continued-strong-revenue-growth-in-q1-2012-5061
Evotec AG and 4-Antibody AG form strategic collaboration to innovate antibody selection
Evotec AG and 4-Antibody AG today announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-and-4-antibody-ag-form-strategic-collaboration-to-innovate-antibody-selection-5059
Evotec AG announces multi-year agreement with The United States Environmental Protection Agency (EPA)
Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-announces-multi-year-agreement-with-the-united-states-environmental-protection-agency-epa-5055
Evotec grants exclusive rights on EVT 401 in China to Conba Pharmaceutical
Evotec AG and Conba Pharmaceutical Co., Ltd. announced today the grant of a development and marketing license on EVT 401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease and endometriosis in China. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-grants-exclusive-rights-on-evt-401-in-china-to-conba-pharmaceutical-5053